Figure 1.

WISP1 is highly increased in inflamed mucosa and LPMCs of IBD patients. (a) qRT-PCR analysis of WISP1 in colonic samples from healthy controls (HC, n = 21), inflamed mucosa of active Crohn's disease (CD) patients (A-CD, n = 24), active UC patients (A-UC, n = 21), CD patients in remission (R-CD, n = 20), and UC patients in remission (R-UC, n = 18). (b) and (c) Representative western blots of WISP1 and β-actin in total proteins from colonic samples (b) and LPMCs (c) from HC (n = 13), CD patients (n = 16), and UC patients (n = 12). Right panel in (b) and (c) shows the quantitative analysis of WISP1/β-actin ratio. (d) Relative expression of WISP1 in intestinal mucosa from inflamed and uninflamed intestinal mucosa from the same patients with IBD (n = 13). (e) WISP1 expression in different subsets of immune cells. Peripheral blood B cells, CD4⁺ T cells, CD8⁺ T cells, monocytes, and neutrophils (1 × 10⁶ for each subset) were extracted from 10 healthy donors, and WISP1 expression was determined by qRT-PCR. (f) Mucosal biopsies were taken from 13 patients with CD, 12 patients with UC, and 10 healthy controls. The levels of mRNA for WISP1 were detected by qRT-PCR. Gene expression was normalized to GAPDH mRNA levels in each sample. (d) Paired Student's t-test and (a, b, c, and f) one-way ANOVA. ^∗ p < 0.05, ^∗∗ p < 0.01, and ^∗∗∗ p < 0.001; data are expressed as mean ± s.e.m. for all samples.